Variable | Overall (N = 8) |
---|---|
Median (min, max) age at first infusion, years | 37.7 (22.1, 45.2) |
Age at time of first infusion (years) category | |
18 to <30 years | 2 (25.0) |
30 to <40 years | 3 (37.5) |
40 to <50 years | 3 (37.5) |
Race | |
Asian | 1 (12.5) |
White | 7 (87.5) |
ADAMTS13 activity >5% | 8 (100) |
Extrarenal signs or symptoms of aHUS prior to first infusion of drug | 6 (75) |
Baseline laboratory values, median (min, max) a | |
Platelet count, ×109/L | 119 (36, 473) |
LDH, U/L | 576 (280, 876) |
Serum creatinine, μmol/L | 408 (51, 758) |
HGB, g/L | 72.8 (63, 105.5) |
eGFR, mL/min/1.73 m2(b) | 10.0 (10, 18) |
Median (min, max) time from delivery to first dose, days | 11 (5, 19) |
ICU care required | 7 (87.5) |
Median (min, max) stay in ICU, days | 9 (2, 21) |
Received PE/PI related to this TMA prior to first infusion of drug | 6 (75) |
On dialysis within 5 days of first dose | 5 (62.5) |
Median (min, max) time on dialysis prior to first dose, days | 5 (4, 8) |
Patients with ≥1 identified pathogenic variant or autoantibody | 2 (25) |
CFB pathogenic variant | 1 (12.5) |
Anti-CFH antibodies | 1 (12.5) |
None identified | 5 (65.5) |
Data not available | 1 (12.5) |